August 2026

Contents

Conference reports

• AIDS 2026: PrEP efficacy depends on adherence not biology – PrEP access depends on politics

• AIDS 2026: Free access to opening ceremony and rapporteur summaries

• AIDS 2026: The promise of bNAbs in HIV cure-related research in chronic infection

• AIDS 2026: UNAIDS special report publishes data to 2025

• AIDS 2026: New HIV drugs in the ART pipeline

Antiretrovirals

• US FDA approves once-daily oral bictegravir/lenacapavir as simplified HIV combination (Bixlenvo)

• NHS England finally approves lenacapavir for ART